文献速递心脑血管急症中毒与环境急症

拟交感类娱乐性药物急性心血管并发症

Acute cardiovascular complications of sympathomimetic recreational drug use.
PubMed 文献 · Clin Toxicol (Phila) · 2026-07-27
一句话结论疑似拟交感娱乐药物致急性心血管症状时,多数按标准心血管指南处理,但需早期镇静、选择性毒检、谨慎选β阻滞剂。

本文为叙述性综述,检索PubMed至2024年3月1日,汇总可卡因、安非他命类兴奋剂及合成卡西酮等拟交感娱乐药物相关急性心血管并发症。此类药物通过儿茶酚胺过量、受体激活、离子通道干扰及直接心肌毒性致病,可卡因还经内皮素-1致血管痉挛和血栓形成并阻断钠、钾通道。急性表现包括胸痛、急性冠脉综合征、心律失常、心肌病和心源性猝死,可模仿经典心脏综合征但可能更重。诊断从详细病史开始,自报用药常不可靠;处理应个体化,镇静、降压药和双联抗血小板为基础,必要时用血管扩张剂,选择性患者可用具α阻滞作用的β阻滞剂。

要点

  • 可卡因相关胸痛患者可用HEART路径进行风险分层,低危病例可据此安全离院(原文表述为may guide safe discharge)。
  • 自报娱乐药物使用常不可靠,诊断应从详细病史开始,并据症状选做心电图、心脏生物标志物和超声心动图。
  • 毒物检测仅在临床有指征且预期影响临床决策时考虑,结果须结合临床发现解读。
  • 处理基础为镇静、降压药和双联抗血小板治疗,有指征时用血管扩张剂;β阻滞剂须按具体药物谨慎选择。
  • 早期药物咨询和转诊对减少复发至关重要,应纳入急性诊疗路径。

适用人群与场景

  • 疑似使用可卡因、安非他命类兴奋剂或合成卡西酮等拟交感娱乐药物、出现急性心血管症状的患者,场景为急诊科。
  • 原文未明确列出纳入/排除人群及院前或ICU场景的具体限定。

诊断标准与关键阈值

  • 原文未给出具体诊断标准名称、评分界值或启动/停止阈值;仅提及可卡因相关胸痛患者可用HEART路径进行风险分层以指导低危病例安全离院。

处置流程与药物剂量

  • 第一步:详细采集病史(自报用药常不可靠),据症状选做心电图、心脏生物标志物和超声心动图以风险分层和识别潜在病理。
  • 第二步:毒物检测仅在临床有指征且预期影响临床决策时考虑,结果须结合临床发现解读。
  • 第三步:处理个体化,镇静、降压药和双联抗血小板治疗为基础,有指征时用血管扩张剂。
  • 第四步:具α阻滞作用的β阻滞剂可能在选择性患者中有益,须根据涉及的具体物质谨慎选择。
  • 第五步:早期药物咨询和转诊以减少复发。
  • 原文未给出具体药物剂量、单位、给药途径、频次或疗程。

红旗征与不能漏的情况

  • 急性心血管表现包括胸痛、急性冠脉综合征、心律失常、心肌病和心源性猝死;表现可模仿经典心脏综合征但可能更严重,尤其见于无传统危险因素的年轻患者。
  • 原文未明确列出需立刻处理或不能漏诊的具体红旗征及对应处理。

研究设计与关键结果

  • 研究类型为叙述性综述,PubMed检索自建库至2024年3月1日,检索词为心血管症状和并发症与拟交感娱乐药物相关术语的组合。
  • 机制:拟交感物质经儿茶酚胺过量、受体激活、离子通道干扰和直接心肌毒性致病;可卡因另经内皮素-1致血管痉挛和血栓形成并阻断钠、钾通道;安非他命类和合成卡西酮放大儿茶酚胺释放。

证据类型、等级与局限

  • 证据类型为叙述性综述(narrative review),原文未给出证据等级或推荐强度。
  • 局限:叙述性综述,非系统评价,未提供定量合并结果;原文未明确列出其他局限。

对床旁实践的改变

  • 多数疑似拟交感药物相关急性心血管症状按标准指南心血管处理,但需特定修改:毒检选择性使用、早期镇静降低交感过度活跃、按物质谨慎选β阻滞剂。
  • 可据此避免过度治疗和治疗不足;原文未明确适用与不适用人群及常见陷阱的具体清单。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

INTRODUCTION: Recreational drug use is rising globally, with significant cardiovascular implications. Sympathomimetic substances such as cocaine, amfetamine(amphetamine)-type stimulants and synthetic cathinones are increasingly associated with emergency department presentations and acute cardiac events. Despite this growing burden, standardized guidance for diagnosing and managing acute sympathomimetic recreational drug-related cardiovascular complications remains limited.

METHODS: A narrative review of the literature was conducted to identify acute cardiovascular complications associated with commonly used recreational drugs. A PubMed search was performed from database inception to 1 March 2024 using combinations of cardiovascular symptoms and cardiovascular complications with terms related to sympathomimetic recreational drug use.

RESULTS: These substances exert potent sympathomimetic effects through catecholamine excess, and cause receptor activation, ion channel interference, and direct myocardial toxicity. Cocaine additionally induces vasospasm and thrombosis via endothelin-1 and causes sodium channel and potassium channel blockade. Amfetamine-type stimulants and synthetic cathinones amplify catecholamine release, contributing to arrhythmia, ischemia, and myocardial injury. Acute cardiovascular manifestations include chest pain, acute coronary syndrome, arrhythmias, cardiomyopathy, and sudden cardiac death. Presentations often mimic classical cardiac syndromes but may be more severe, especially in younger patients without traditional risk factors. Diagnosis begins with detailed history-taking, although self-reported drug use is frequently unreliable. Depending on symptoms, electrocardiography, cardiac biomarkers and echocardiography may be essential for risk stratification and identifying the underlying pathology. Toxicological testing may be considered when clinically indicated and should be interpreted in conjunction with clinical findings. For cocaine associated chest pain patients, risk stratification with the HEART pathway may guide safe discharge in low-risk cases. Management should be individualized based on the specific recreational drug involved and the presenting symptoms. Sedation, antihypertensives, and dual antiplatelet therapy are foundational, with vasodilators when indicated. Beta-blockers with alpha-blocking properties may be beneficial in selected patients. Early drug counselling and referral are critical to reduce recurrence.

DISCUSSION: In most cases, evaluation and management of acute cardiovascular symptoms in patients with suspected sympathomimetic drug use should follow standard guideline-based cardiovascular care. However, specific modifications may be required, including selective use of toxicological testing when it is expected to influence clinical decision-making, early sedation to reduce sympathetic overactivity, and cautious selection of beta-blockers depending on the substance involved. Awareness of these distinctions is essential to avoid both under- and overtreatment.

CONCLUSION: Clinicians must recognize the acute cardiovascular risks of sympathomimetic recreational drugs and integrate routine drug screening, tailored management, and addiction intervention into acute care pathways to improve outcomes and reduce morbidity.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Gresnigt FMJ. Acute cardiovascular complications of sympathomimetic recreational drug use. Clin Toxicol (Phila). 2026. PMID: 42504704. doi:10.1080/15563650.2026.2701369

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。